🧬 Endocrinology Update: Gamified Insulin Pump, AI in Thyroid Cancer, Teplizumab Approval and More
Stay on top of the latest breakthroughs in endocrinology news that are shaping the future of diabetes care, thyroid treatment, AI in oncology, and more. This update brings you the most impactful innovations from global leaders in clinical research, biotech, and digital health.
📌 In This Episode:
🚨 Discover the top 10 breakthroughs in endocrinology that are shaping the future of diabetes care, thyroid treatment, AI in oncology, and more. This update brings you the most impactful innovations from global leaders in clinical research, biotech, and digital health.
🚀 Modular Medical introduces its Pivot Patch Insulin Pump with integrated gamified diabetes training, unveiled at ADCES 2025. FDA submission is expected this October.
🧰 Lupin enters the U.S. market with a new emergency glucagon injection, bioequivalent to Eli Lilly’s formulation and valued at $122 million annually.
👁️ Prevent Blindness forms a new advisory committee focused on diabetes-related eye health, launching pilot programs in North Carolina.
🧪 TriSalus reports a 73 percent reduction in thyroid gland volume through pressure-enabled embolization, with no major complications in early trials.
🧠 Marea Therapeutics begins a first-in-human trial for MAR002, a once-daily GH receptor antagonist targeting elevated IGF-1 levels in acromegaly.
🇮🇳 Eli Lilly launches the Mounjaro Kwikpen in India at a starting dose of ₹14,000, offering six strengths and competing with Novo Nordisk’s Wegovy.
🧬 LINC00162 silencing through siRNA boosts sorafenib sensitivity in thyroid cancer by enhancing apoptosis and reducing cancer cell migration.
🧫 An AI model using radiomics-based CT data predicts lymph node recurrence in thyroid cancer with greater than 94 percent accuracy, improving treatment planning.
🇸🇬 Singapore researchers develop a first-trimester blood test for gestational diabetes that eliminates fasting and long testing protocols, enabling earlier intervention.
🇬🇧 The UK approves Teplizumab, the first immunotherapy for delaying the onset of type 1 diabetes by an average of 3 years in patients aged 8 and above.
📢 Stay Ahead in Endocrinology Research!
✅ Like, share, and subscribe for weekly updates on endocrinology and diabetes innovations
#Endocrinology #DiabetesCare #ThyroidCancer #GLP1 #Acromegaly #GestationalDiabetes #InsulinPump #AIinHealthcare #Teplizumab #ClinicalTrials #LQVentures #HealthcareInnovation #MedicalResearch #PharmaNews
“